Download PDF
Zentralbl Chir 2003; 128(5): 411-418
DOI: 10.1055/s-2003-40038
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Adjuvante Therapie des Pankreaskarzinoms

Adjuvant treatment of pancreatic cancerH. Oettle1
  • 1Charité Campus Virchow-Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin, Medizinische Klinik und Poliklinik m. S. Hämatologie und Onkologie
Further Information

Publication History

Publication Date:
18 June 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Prognose des Pankreaskarzinoms ist in allen Stadien schlecht. Die einzige Heilungschance besteht in der vollständigen Resektion des Tumors. Allerdings sind nur maximal 10-25 % der Patienten überhaupt operabel, und selbst nach kurativ intendierter Operation beträgt die mediane Überlebenszeit nur etwa 18 Monate. Neben Lokalrezidiven kommt es nach der Operation auch meist frühzeitig zu systemischer Metastasierung. Zur Wirksamkeit einer adjuvanten, postoperativen Therapie liegen widersprüchliche Ergebnisse vor. In einigen Studien wurde mit einer kombinierten Strahlen- und Chemotherapie eine Verlängerung der Überlebenszeit erreicht, in anderen nicht. Die perkutane Bestrahlung kann durch eine intraoperative Radiotherapie ergänzt werden, wobei dies jedoch allenfalls die lokale Tumorkontrolle verbessert. Auch für die Wirksamkeit der alleinigen adjuvanten systemischen Chemotherapie gibt es bislang keine überzeugenden Beweise. Leider trugen auch die Ergebnisse der randomisierten Studie ESPAC-1 wegen des problematischen Designs nicht zu einer Klärung dieser Sachlage bei. Aufschlüsse erhofft man sich jetzt von neueren Studien, in denen auch der palliative Therapiestandard Gemcitabin in der adjuvanten Situation geprüft wird.

Abstract

The prognosis of pancreatic cancer is poor at any stage. The complete resection of the tumour offers the only chance of cure, but 10-25 % of the patients at most present with operable disease, and median survival following surgery with curative intention is 18 months. Local recurrence is often accompanied or rapidly followed by distant metastasis. Studies of postoperative (adjuvant) treatment have yielded contradictory results. Combined radiochemotherapy resulted in improved survival in a few studies while others failed to demonstrate any survival benefit. Intraoperative radiation therapy given in addition to percutaneous irradiation may improve local tumour control at best. At present only few data support the benefit of adjuvant systemic chemotherapy alone. Unfortunately, the recently completed ESPAC-1 study was not very helpful in settling this issue due to its problematic design. Therefore, the results of ongoing studies of adjuvant chemotherapy are eagerly awaited. These studies have also included arms with gemcitabine, the current standard for palliative treatment of pancreatic cancer, and will hopefully allow firm conclusions as to the role of postoperative chemotherapy.

Schlüsselwörter

Pankreaskarzinom - adjuvante Therapie - Pankreatektomie - Chemotherapie - Strahlentherapie

Key words

Pancreatic carcinoma - pancreatic cancer - adjuvant therapy - pancreatectomy - chemotherapy - radiotherapy

Literatur

  • 1 A multi- institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group.  Ann Surg. 1979;  189(2) 205-208
    PubMedSearch in Google Scholar
  • 2 Abrams R A. et al . Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.  Int J Radiat Oncol Biol Phys. 1999;  44(5) 1039-1046
    CrossrefPubMedSearch in Google Scholar
  • 3 Amano H. et al .Five-year results of a randomized Study of postoperative adjuvant chemotherapy for resected pancreatic-biliary carcinomas. Proc. ASCO 1999
  • 4 Bakkevold K E. et al . Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study.  Eur J Cancer. 1993;  29 a(5) 698-703
    PubMedSearch in Google Scholar
  • 5 Beger H. et al . Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: signifikant reduction of occurrence of liver metastasis.  World J Surg. 1999;  23(9) 946-949
    CrossrefPubMedSearch in Google Scholar
  • 6 Beger H G, Link K H, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study.  Hepatogastroenterology. 1998;  45(21) 638-643
    PubMedSearch in Google Scholar
  • 7 Bosset J F. et al . Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study.  Radiother Oncol. 1992;  24(3) 191-194
    CrossrefPubMedSearch in Google Scholar
  • 8 Bramhall S R. et al . Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study [see comments].  Br J Surg. 1995;  82(1) 111-115
    CrossrefPubMedSearch in Google Scholar
  • 9 Büchler M. et al . A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.  Cancer. 1991;  68(7) 1507-1512
    PubMedSearch in Google Scholar
  • 10 Büchler M. et al . Studies of pancreatic cancer utilizing monoclonal antibodies.  Int J Pancreatol,. 1990;  7(1-3) 151-157
    PubMedSearch in Google Scholar
  • 11 Burris H A. 3rd. et al . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [see comments].  J Clin Oncol. 1997;  15(6) 2403-2413
    CrossrefPubMedSearch in Google Scholar
  • 12 Cameron J L. et al . Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.  Am J Surg. 1991;  161 (1) 120-124
    CrossrefPubMedSearch in Google Scholar
  • 13 Cameron J L. Long-term survival following pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas.  Surg Clin North Am. 1995;  75(5) 939-951
    CrossrefPubMedSearch in Google Scholar
  • 14 Chakravarthy A. et al .Preliminary results of a phase II study of adjuvant combined modality therapy for resected pancreatic and periampullary adenocarcinoma using local irridation,. 5-FU, LV, Dipyridamole and Mitimycin C. Proc. ASCO 1998
  • 15 Edge S B. et al . Pancreas cancer resection outcome in American University centers in 1989 -1990.  Cancer. 1993;  71(11) 3502-3508
    PubMedSearch in Google Scholar
  • 16 Foo M L. et al . Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ± 5 fluorouracil.  Int J Radiat Oncol Biol Phys. 1993;  26(3) 483-489
    PubMedSearch in Google Scholar
  • 17 Friedman N. et al .Adjuvant Radiation and Continuous 5-FU Followed by Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer. Proc. ASCO 1999
  • 18 Garton G R. et al . High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer.  Int J Radiat Oncol Biol Phys. 1993;  27(5) 1153-1157
    PubMedSearch in Google Scholar
  • 19 Gastrointestinal Tumour Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer.  Cancer. 1997;  59(12) 2006-2010
    PubMedSearch in Google Scholar
  • 20 Glaser K, Bodner E, Kingler A. Adjuvant intraoperative radiation therapy during pancreatectomy. Standards in Pancreatic Surgery, ed. M. Büchler and P. Malfertheiner. Springer-Verlag, Berlin, Heidelberg, New York 1993; 676-681
  • 21 Griffin J F. et al . Patterns of failure after curative resection of pancreatic carcinoma.  Cancer. 1990;  66(1) 56-61
    PubMedSearch in Google Scholar
  • 22 Gudjonsson B. Cancer of the pancreas. 50 years of surgery.  Cancer. 1987;  60(9) 2284-2303
    CrossrefPubMedSearch in Google Scholar
  • 23 Hoffman H P. et al .A phase 1 study of preoperative Gemcitabine (GEM) with radiation therapy (RF) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PaC). Proc. ASCO 1998
  • 24 Ishikawa O. et al . Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer.  Hepatogastroenterology. 1997;  44(18) 1541-1546
    PubMedSearch in Google Scholar
  • 25 Kalser M H, Ellenberg S S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.  Arch Surg. 1985;  120(8) 899-903
    CrossrefPubMedSearch in Google Scholar
  • 26 Kayahara M. et al . An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging.  Cancer. 1993;  72(7) 2118-2123
    CrossrefPubMedSearch in Google Scholar
  • 27 Klinkenbijl J. et al . Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and periampullary region: a phase III-trial of the EORTC-GITCCG.  Eur J Cancer. 1997;  33 274
    PubMedSearch in Google Scholar
  • 28 Klinkenbijl J H. et al . Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III-trial of the EORTC gastrointestinal tract cancer cooperative group.  Ann Surg. 1999;  230(6) 776-782
    CrossrefPubMedSearch in Google Scholar
  • 29 Kudrimoti M. et al .Concurrent infusional Gemcitabine and Radiation in the Treatment of advanced unresectable GI-malignancy: A Phase I/II Study. Proc. ASCO 1999
  • 30 Lillemoe K D, Pitt H A. Palliation. Surgical and otherwise.  Cancer. 1996;  78(Suppl 3) 605-614
    CrossrefPubMedSearch in Google Scholar
  • 31 Lillemoe K D. Current management of pancreatic carcinoma.  Ann Surg. 1995;  221(2) 133-148
    PubMedSearch in Google Scholar
  • 32 Link K H. et al . Resection and radiochemotherapy of pancreatic cancer - the future?.  Langenbecks Arch Surg. 1998;  383(2) 134-144
    PubMedSearch in Google Scholar
  • 33 Lionetto R. et al . No standard treatment is available for advanced pancreatic cancer.  Eur J Cancer. 1995;  31(6) 882-887
    CrossrefPubMedSearch in Google Scholar
  • 34 Lygidakis N J, Stringaris K. Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a prospective randomized study.  Hepatogastroenterology. 1996;  43(9) 671-680
    PubMedSearch in Google Scholar
  • 35 Lygidakis N J. et al . Pancreatic resection for pancreatic carcinoma combined with neo- and adjuvant locoregional targeting immuno-chemotherapy - a prospective randomized study.  Hepatogastroenterology. 1998;  45(20) 396-403
    PubMedSearch in Google Scholar
  • 36 McGrath P C, Sloan D A, Kenady D E. Surgical management of pancreatic carcinoma.  Semin Oncol. 1996;  23(20) 200-212
    PubMedSearch in Google Scholar
  • 37 Moertel C G. et al . Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6 000 rads) radiation alone, moderate dose radiation (4 000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.  Cancer. 1981;  48(8) 1705-1710
    CrossrefPubMedSearch in Google Scholar
  • 38 Mohiuddin M. et al . Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.  J Clin Oncol. 1995;  13(11) 2764-2768
    PubMedSearch in Google Scholar
  • 39 Moore M. et al .Proc ASCO 2002; 21: Abstr 930
  • 40 Morganti A G. et al . Preoperative radiochemotherapy in pancreatic cancer: preliminary results.  Tumori. 1999;  85(Suppl 1) S27-S32
    PubMedSearch in Google Scholar
  • 41 Neoptolemos J P. et al . ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer.  Digestion. 1997;  58(6) 570-577
    PubMedSearch in Google Scholar
  • 42 Neoptolemos J P. et al . Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.  Lancet. 2001;  358 1576-1585
    CrossrefPubMedSearch in Google Scholar
  • 43 Neoptolemos J P. et al . Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.  Ann Surg. 2001;  234 758-768
    CrossrefPubMedSearch in Google Scholar
  • 44 Ozaki H. et al . Effectiveness of multimodality treatment for resectable pancreatic cancer.  Int J Pancreatol. 1990;  7(1-3) 195-200
    PubMedSearch in Google Scholar
  • 45 Paulino A C. Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure.  Am J Clin Oncol. 1999;  22(5) 489-494
    CrossrefPubMedSearch in Google Scholar
  • 46 Picozzi V. et al .Adjuvant combined modality therapy for resected, high-risk adenocarcinoma of the pancreas using Cisplatin, 5-Fluorouracil, and Alpha-Interferon as radiosensitizing agents: A Phase-II-Study. Proc. ASCO 1999
  • 47 Picus J. et al .A phase II trial of continuous infusion 5-FU with 3-D conformal radiation in the adjuvant treatment of pancreatic, ampullary and biliary cancers. Proc. ASCO 1998
  • 48 Pisters P W. et al . Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.  J Clin Oncol. 1998;  16(12) 3843-3850
    PubMedSearch in Google Scholar
  • 49 Rattner D W. Pancreatic cancer in 1992: has any progress been noted.  Mayo Clin Proc. 1992;  67(9) 907-909
    PubMedSearch in Google Scholar
  • 50 Rich T A, Evans D B. Preoperative combined modality therapy for pancreatic cancer.  World J Surg. 1995;  19(2) 264-269
    CrossrefPubMedSearch in Google Scholar
  • 51 Roldan G E. et al . External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.  Cancer. 1988;  61(6) 1110-1116
    PubMedSearch in Google Scholar
  • 52 Rothenberg M L. et al . A phase II-trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.  Ann Oncol. 1996;  7(4) 347-353
    PubMedSearch in Google Scholar
  • 53 Shibamoto Y. et al . High dose, external beam and intraoperative radiotherapy in the treatment of resectable and unresectable pancreatic cancer.  Int J Radiat Oncol Biol Phys. 1990;  19(3) 605-611
    PubMedSearch in Google Scholar
  • 54 Splinter T A. et al . Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.  J Cancer Res Clin Oncol. 1989;  115(2) 200-202
    CrossrefPubMedSearch in Google Scholar
  • 55 Staley C A. et al . Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.  Am J Surg. 1996;  17(1) 1 118-124
    PubMedSearch in Google Scholar
  • 56 Storniolo A M. et al . An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.  Cancer. 1999;  85(6) 1261-1268
    CrossrefPubMedSearch in Google Scholar
  • 57 Trede M, Schwall G, Saeger H D. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality.  Ann Surg. 1990;  211(4) 447-458
    PubMedSearch in Google Scholar
  • 58 Trede M. Treatment of pancreatic carcinoma: the surgeon’s dilemma.  Br J Surg. 1987;  74(2) 79-80
    PubMedSearch in Google Scholar
  • 59 Trede M. et al . Resection of pancreatic cancer - surgical achievements.  Langenbecks Arch Surg. 1998;  383(2) 121-128
    PubMedSearch in Google Scholar
  • 60 Watanapa P, Williamson R C. Surgical palliation for pancreatic cancer: developments during the past two decades.  Br J Surg. 1992;  79(1) 8-20
    CrossrefPubMedSearch in Google Scholar
  • 61 Whittington R. et al . Adjuvant therapy of resected adenocarcinoma of the pancreas.  Int J Radiat Oncol Biol Phys. 1991;  21(5) 1137-1143
    PubMedSearch in Google Scholar
  • 62 Willett C G. et al . Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.  Ann Surg. 1993;  217(2) 144-148
    PubMedSearch in Google Scholar
  • 63 Yeo C J. et al . Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.  Ann Surg. 1995;  221(6) 721-731
    CrossrefPubMedSearch in Google Scholar
  • 64 Yeo C J. et al . Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.  Ann Surg. 1997;  225(5) 621-633
    CrossrefPubMedSearch in Google Scholar
  • 65 Yeo C J. et al . Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.  Ann Surg. 1997;  226(3) 248-257
    CrossrefPubMedSearch in Google Scholar
  • 66 Zerbi A. et al . Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer.  Cancer. 1994;  73(12) 2930-2935
    PubMedSearch in Google Scholar

Priv.-Doz. Dr. Helmut Oettle

Charité, Campus Virchow-Klinikum · Medizinische Fakultät der Humboldt Universität zu Berlin · Medizinische Klinik und Poliklinik m. S. Hämatologie und Onkologie

Augustenburger Platz 1

13353 Berlin

Phone: 00 49/0 30/4 50 55 32 22

Fax: 00 49/0 30/4 50 55 39 59

Email: pankreas@charite.de